Live
- From Blueprints to Skylines: The Journey of Hyderabad’s Top Builders
- PM Modi urges Indian diaspora to participate in 'Bharat Ko Janiye' quiz
- Koraput: Four die as truck hits bike
- Odisha begins Mahtab’s 125th birth anniv celebrations
- Bhadrak: Four held for murder of ex-Sarpanch
- National honour for Odia chest specialist
- Sold newborn traced in Raipur
- AIBOC warns of agitation
- 4 held from Gujarat in ‘digital arrest’ case
- 10 held for attack on MLA Himanshu
Dr Reddy's reports Rs 570 crore loss for Q3
Profits impacted due to trigger-based impairment charge taken on a few products
Hyderabad: Dr Reddy's Laboratories Limited's suffered nearly Rs 570 crore loss for the quarter ended December 31 against Rs 485 crore profit after tax during the corresponding period of FY19, the company said on Monday. Revenues for the quarter under discussion was up by 14 per cent to Rs 4,384 crore against Rs 3,850 crore in Q3 of last fiscal.
Co-Chairman and MD, GV Prasad said, "The current quarter performance has been good across all our businesses and we achieved strong EBITDA margins.
The profits were impacted due to trigger-based impairment charge taken on a few products including Nuvaring. We continue to focus on execution and have made significant progress on quality systems and operational efficiencies."
Q3 FY20 financials include an impairment charge of Rs 1,320 crore million on some of the Company's products forming part of Global Generics and Proprietary Products segments, the drug maker said.
In December 2019 there had been a generic launch and an authorised generic launch for the product Nuvaring, which has led to a considerable erosion in the value of this product for the company, and accordingly the drug maker has taken an impairment charge of Rs 110 crore
"In addition to this, considering the current market dynamics, we have taken an impairment charge of Rs 210 crore on the intangibles pertaining to other products. In total, we have taken an impairment of Rs 1,320 crore on the intangible assets for this quarter," it said.
Revenues from Global Generics segment was reported at Rs 3,590 crore, year-on-year growth of 15 per cent, primarily driven by Europe, emerging markets and India.
Revenues from North America was at Rs 1,600 crore, a year-on-year growth of eight per cent the company launched five new products (Bortezomib injection, Doxercalciferol, Deferasirox dispersable tabs, Deferasirox film coated tabs, Sodium Nitroprusside injection) during the quarter in the US market.
Revenues from Emerging Markets was Rs 920 crore and India at Rs 720 crore. Revenues from Pharmaceutical Services and Active Ingredients was reported at Rs 690 crore a growth 16 per cent over the same quarter last year.
Dr Reddy's spent Rs 390 crore towards Research and Development expenses during October-December quarter.
